SCHEMBL20204972

SCHEMBL20204972

O=C(Nc1cnc(F)cc1N1CCOCC1)c1ccnc(Cl)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
ALOX15 P16050 1/20 0.51
MAPK1 P28482 1/20 0.51
CYP1A2 P05177 1/20 0.48
POLB P06746 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
IRAK4 Q9NWZ3 3/20 0.48
GSK3B P49841 2/20 0.46
GSK3A P49840 1/20 0.46
ALDH1A1 P00352 4/20 0.46
NPSR1 Q6W5P4 1/20 0.46
SMN1; SMN2 Q16637 5/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPT P10636 3/20 0.45
LMNA P02545 2/20 0.45
GAA P10253 2/20 0.45
HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29939856 1.00 TSHR (0.51) TSHRL3MBTL1ALOX15MAPK1CYP1A2
SCHEMBL20189783 0.88 GSK3A (0.60) TSHRL3MBTL1ALOX15MAPK1IRAK4
SCHEMBL20204994 0.86 GSK3A (0.54) TSHRL3MBTL1ALOX15MAPK1CYP1A2
SCHEMBL20204946 0.85 IRAK4 (0.45) TSHRL3MBTL1ALOX15MAPK1CYP1A2
SCHEMBL29938993 0.85 IRAK4 (0.45) TSHRL3MBTL1ALOX15MAPK1CYP1A2
SCHEMBL29939117 0.84 MAPK1 (0.52) TSHRL3MBTL1ALOX15MAPK1CYP1A2
SCHEMBL20205173 0.84 MAPK1 (0.52) TSHRL3MBTL1ALOX15MAPK1CYP1A2
SCHEMBL20205219 0.84 GSK3A (0.49) TSHRL3MBTL1ALOX15MAPK1CYP1A2
SCHEMBL29939489 0.84 GSK3A (0.49) TSHRL3MBTL1ALOX15MAPK1CYP1A2
SCHEMBL20205183 0.84 GSK3A (0.53) TSHRL3MBTL1ALOX15MAPK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110545817-B GSK-3 inhibitors 百时美施贵宝公司 2022-11-15 CN disclosed
EP-3544613-B1 GSK-3 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-06-09 EP disclosed
EP-3544613-B1 GSK-3 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-06-09 EP disclosed
US-10752609-B2 GSK-3 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-08-25 US disclosed
US-10752609-B2 GSK-3 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-08-25 US disclosed
CN-110545817-A GSK-3 inhibitors SQUIBB BRISTOL MYERS COMPANY 2019-12-06 CN disclosed
US-20190315714-A1 GSK-3 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-10-17 US disclosed
US-20190315714-A1 GSK-3 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-10-17 US disclosed
WO-2018098412-A1 GSK-3 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190315714-A1 GSK-3 INHIBITORS GSK3B, GSK3A, GSKIP TSHR 3553/4885L3MBTL1 2113/4885ALOX15 3256/4885
US-10752609-B2 GSK-3 inhibitors GSK3B, GSK3A, GSKIP TSHR 3553/4885L3MBTL1 2113/4885ALOX15 3256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.